百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Submitted by cheukllui3 on
Anti-Cancer
Chemical Biology
Chemistry
Novel tridimensional anticancer agents developed to fight against drug-resistant cancer cells

A research team co-led by chemists from City University of Hong Kong (CityU) recently discovered novel, highly effective anticancer agents with tridimensional structures, which have high anticancer activity, low toxicity and the ability to overcome drug resistance in cancer cells. The findings help provide a new direction for anticancer drug development.

Cancer has long been a devastating disease, which affects millions of people worldwide. Despite advances in treatment, current anticancer drugs often have limited effectiveness, lack of cancer selectivity, serious side effects and drug resistance in cancer cells.

“The structure of drugs greatly affects their anticancer performance,” explained Dr. Guangyu Zhu in the Department of Chemistry at CityU. “Most anticancer drugs have planar structures; developing new compounds with tridimensional structures may provide an opportunity to address the limitations of current anticancer drugs.”

In collaboration with researchers from The Hong Kong University of Science and Technology (HKUST), the team tested a new class of tridimensional and chiral compounds, which exhibit promising anticancer activity and present action mechanisms that are distinct from conventional anticancer drugs to overcome drug resistance.

anticancer agents
The half maximal inhibitory concentration (IC50 value) of synthetic lead compounds and clinical drug doxorubicin (DOX) in lung cancer stem cells and normal cells after incubation for 72 hours. Credit: Dr. Guangyu Zhu’s Research Group / City University of Hong Kong

The team first developed a new, highly efficient catalytic synthetic strategy to obtain a novel class of tridimensional and chiral tetraarylmethane compounds that presented better anticancer activity and lower toxicity than the clinical anticancer drug doxorubicin.

In their experiments, the research team tested the compounds with cancer cells in vitro, using doxorubicin as a control. They found that the tetraarylmethane compounds were more cytotoxic to cancer cells, including lung cancer stem cells (LCSCs), which are notorious for their drug resistance to clinical chemotherapeutic drugs, causing treatment failure. The compound also exhibited better cancer cell selectivity as it caused less harm to normal living cells, suggesting lower toxicity.

anticancer agents
SAR analysis of the synthetic compounds. The key factors that
contribute to the anticancer activity of this type of compound are indicated. The presence of certain substituents, including halogen and hydroxyl groups, at certain positions in the tetraarylmethane compounds significantly improves cytotoxicity. TMS, trimethylsilyl; Me, methyl. Credit: ? Tan, X. et al.: https://www.nature.com/articles/s44160-022-00211-4

The team further analyzed the structure-activity relationship of synthesized compounds. They found that the presence of certain substituents, including halogen and hydroxyl groups, at certain positions of the tetraarylmethane compounds significantly improved their cytotoxicity to cancer cells. Upon treatment with the synthesized compound, some cancer cells started to die, as organelle swelling, cell membrane permeabilization, nuclear shrinkage and fragmentation were observed. This suggests that necrotic cell death might have been triggered by the tetraarylmethane compounds.

In the fight against cancer, the majority of anticancer drugs currently available rely on the activation of apoptotic pathways to eliminate cancer cells. However, a promising new avenue of research for reducing drug resistance lies in the development of novel anticancer agents that target alternative cell death pathways. In their experiments, the team found that these innovative compounds induced a different cell death pathway. This suggests that the compounds can bypass the resistance mechanisms generated by conventional drugs, making them highly desirable for further exploration in the field of cancer treatment.

“The satisfactory anticancer performance and unique mechanism make these compounds potential candidates for anticancer agents for further development,” said Dr. Zhu. The team plans to synthesize more compounds and conduct further experiments to evaluate their anticancer performance.

anticancer agents
The synthesised lead compounds induced necroptosis in lung cancer stem cells. The arrows indicate cell membrane permeabilization. Credit: ? Tan, X. et al. https://www.nature.com/articles/s44160-022-00211-4

Their findings were published in the scientific journal Nature Synthesis under the title "Enantioselective synthesis of tetraarylmethanes through meta-hydroxyl-directed benzylic substitution".

The corresponding authors are Dr. Zhu and Professor Jianwei Sun from HKUST. The co-first authors are Dr. Xuefeng Tan from HKUST and Dr. Zhiqin Deng, former postdoc in Dr Zhu’s research group at CityU.

The research received financial support from the National Natural Science Foundation of China, the Science, Technology and Innovation Committee of Shenzhen Municipality, the Hong Kong Research Grants Council, and the Innovation and Technology Commission.

 

This research article originated from CityU Research Stories.

百家乐破战| 百家乐官网真钱送彩金| 百家乐平注秘籍| 大赢家娱乐城怎么样| 百家乐官网U盘下载| 百家乐官网平注法规则| 亚洲顶级赌场 网投领导者| 运城百家乐官网的玩法技巧和规则| 大发888娱乐城casinolm0| 朝阳区| 百家乐如何取胜| 谢通门县| 百家乐赢钱秘籍鹰| 新邵县| 百家乐优惠现金| 沙龙网上娱乐| 百家乐实时路单| 百家乐官网的赚钱原理| 百家乐官网最保险的方法| 犹太人百家乐的玩法技巧和规则| 百家乐官网韩泰阁| 娱乐城注册送38彩金| 百家乐改单软件| 德州扑克怎么算牌| 博士百家乐现金网| 真人百家乐官网轮盘| 利来国际网上| 百家乐发牌牌规| 百家乐官网波音独家注册送彩| 百家乐官网的路怎样看| 大发888官方我的爱好| 查看百家乐赌博| 财神百家乐官网的玩法技巧和规则 | 菲律宾百家乐娱乐| 百家乐官网博百家乐官网的玩法技巧和规则 | 欢乐谷百家乐官网的玩法技巧和规则| 百家乐官网风云论坛| 线上百家乐的玩法技巧和规则| 最好的百家乐官网娱乐场| 立博博彩| 百家乐真钱游戏|